AbCellera Biologics Inc 2025年季度报告

FORM10-Q_________________________________________________________ (Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period endedJune 30, 2025OR oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _________ to _________Commission File Number:001-39781_________________________________________________________ AbCellera Biologics Inc.(Exact Name of Registrant as Specified in its Charter) _________________________________________________________ Registrant’s telephone number, including area code: (604)559-9005_________________________________________________________ Name of each exchange on which registered Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days.YesxNoo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesoNoxAs of August4, 2025, the registrant had298,832,913common shares, no par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets1Condensed Consolidated Statements of Loss and Comprehensive Loss2Condensed Consolidated Statements of Stockholders’ Equity3Condensed Consolidated Statements of Cash Flows4Notes to Unaudited Condensed Consolidated Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations12Item 3.Quantitative and Qualitative Disclosures About Market Risk24Item 4.Controls and Procedures24PART II.OTHER INFORMATIONItem 1.Legal Proceedings25Item 1A.Risk Factors26Item 2.Unregistered Sales of Equity Securities and Use of Proceeds80Item 5.Other Information80Item 6.Exhibits81Signatures82 Summary of the Material and Other Risks Associated with Our Business Our business is subject to numerous material and other risks and uncertainties. You should carefully consider the followinginformation together with the other information appearing elsewhere in this Quarterly Report, including our financial statements andrelated notes hereto. The occurrence of any of the following risks could have a material adverse effect on our business, financialcondition, results of operations and future growth prospects. The risks and uncertainties described below may change over time andother risks and uncertainties, including those that we do not currently consider material, may impair our business. These risks include,but are not limited to, the following: •We have incurred losses in certain years since inception, including in 2025, and we may not be able to generate sufficientrevenue to achieve profitability.•Our quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in thefuture, making it difficult to predict our future operating results and could cause our operating results to fall belowexpectations.•Our commercial success depends on the quality of our antibody discovery and development capabilities, technologicalcapabilities, the advancement of internal programs, and their acceptance by new and existing partners in our industry.•Failure to execute our business strategy could adversely impact our growth and profitability.•Development of a biological molecule is inherently uncertain, and it is possible that none of the antibody drug candidatesdiscovered using our antibody discovery and development capabilities that are further developed by us or our partners willreceive marketing approval or become viable commercial products, on a timely basis or at all.•Our partners have significant discretion in determining when and whether to make announcements, if any, about the statusof our partnerships, including about clinical devel